The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

Figure 2: Proposed treatment algorithm by HR status. Our proposed treatment algorithm reflects a potential treatment option for HR+, HER2 ultralow metastatic breast cancer based on the results of ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

The HEROES trial explores de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using the Signatera test to guide treatment decisions. The trial aims to enroll 170 patients, focusing on ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...